Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 45.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 296,735 shares of the medical equipment provider's stock after purchasing an additional 92,132 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.13% of Hologic worth $18,214,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of Hologic by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after buying an additional 144,838 shares during the period. Victory Capital Management Inc. grew its holdings in Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after acquiring an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Hologic by 3.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after acquiring an additional 129,035 shares in the last quarter. Invesco Ltd. increased its position in shares of Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after purchasing an additional 572,187 shares during the last quarter. Finally, Boston Partners raised its holdings in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Performance

NASDAQ HOLX traded down $0.57 during trading hours on Friday, hitting $64.74. 1,233,581 shares of the stock were exchanged, compared to its average volume of 2,373,435. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The company has a market cap of $14.43 billion, a price-to-earnings ratio of 27.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.55. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The stock has a 50-day moving average of $60.58 and a 200 day moving average of $63.81.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the firm earned $1.03 EPS. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on HOLX shares. Royal Bank Of Canada lowered their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Evercore ISI dropped their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Morgan Stanley decreased their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Stephens dropped their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Hologic presently has an average rating of "Hold" and a consensus target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.